Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR.CD123 NK cells
- Development stage
- Preclinical
- Lead developer
- Ospedale Pediatrico Bambino Gesù
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR.CD123 NK cells is an investigational, off-the-shelf, second-generation chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD123 (interleukin-3 receptor subunit alpha). Developed by the Bambino Gesù Children's Hospital, the therapy utilizes healthy donor-derived peripheral blood NK cells engineered with a retroviral vector expressing an anti-CD123 CAR construct containing a 4-1BB costimulatory domain and a CD3ζ signaling domain. It is designed as an allogeneic cellular immunotherapy for the treatment of CD123-positive hematological malignancies, specifically pediatric acute myeloid leukemia (AML), offering a potentially safer profile with reduced risk of graft-versus-host disease (GvHD) and cytokine release syndrome (CRS) compared to conventional CAR-T cell therapies.
- Other names
- anti-CD123 CAR-NK cellsanti-CD-123 CAR-NK cellsanti-CD 123 CAR-NK cellsCAR.CD123-NK cellsCAR.CD123-engineered NK cells
Beyond the preview
Go deeper on CAR.CD123 NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR.CD123 NK cells.